Newborn’s Own Cord Blood May Be Key to Pediatric Stroke Treatment
By CP Family Network
An FDA-regulated clinical trial will be conducted at the Florida Hospital for Children to investigate the use of a newborn’s own cord blood stem cells in treating a prenatal or perinatal pediatric stroke.
“Our Cerebral Palsy Family Network (CPFN) has been following stem cell research and the impact it can have on children born with cerebral palsy whether the CP is due to in-utero stroke or other brain damage. Because of our extensive reach within the CP community, our families have been asked and have participated in NIH studies including the funding of research projects. These clinical trials are critical to making a better life for children with neurological deficits,” said Giles Manley, Medical Director of CPFN.
The Phase 1 trial is the first to examine the use of newborn autologous stem cell therapy in the treatment of pediatric stroke. Autologous stem cell therapy is the use of a person’s own stem cells to treat a physical problem.
Following this Phase 1 trial, the goal is to develop Phase 2 studies that will further assess safety and measure efficacy in the use of autologous stem cells to improve common symptoms of this condition.
If you are interested in participating in this clinical trial, visit https://www.clinicaltrials.gov/ct2/show/NCT02460484